Cipla, India’s second-largest pharmaceutical company, posted fourth-quarter results on Friday.

What Happened: Cipla’s net profit for the quarter ended March 31 came in at ₹939.04 crore, up 79% from the ₹525.65 crore it had earned in the same quarter last year. This figure beat analyst estimates of ₹897 crore.

The company’s year-ago profit figure was affected by a one-time exceptional item.

The drugmaker’s revenue stood at ₹6,163.24 crore, rising 7.4% from ₹5,739.30 crore a year ago. The figure was slightly lower than street expectations of ₹6,242 crore.

See Also: Polycab’s Share Surge 8% As Profit Beats Estimates, Says No Written Communication On IT Raid

The pharma giant also declared a final dividend of ₹13 per share for the fiscal year ended 2024.

The firm’s EBITDA came in at ₹1,316 crore, up 13% year on year. The company’s quarterly India revenue grew 7% to ₹2,417 crore. Meanwhile, North America revenue shot up 11% to ₹1,875 crore.

“In Albuterol, our market share was in the range of 12-13% as we ended FY24. We have a strategy in place to improve this market share by a few percentage points,” the company said in a press release.

Price Action: Cipla’s share price was down 1.3% at ₹1,340.95 following the earnings announcment. the stock had spent most of the session in positive territory.

Read Next: TCS, Tata Motors And Others Now To Pay ₹200 Cr To Tata Sons Just For Using Brand Name: Report